Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Flor M., Cramer, Jakob P., Dekker, Cornelia L., Dudley, Matthew Z., Graham, Barney S., Gurwith, Marc, Law, Barbara, Perlman, Stanley, Polack, Fernando P., Spergel, Jonathan M., Van Braeckel, Eva, Ward, Brian J., Didierlaurent, Arnaud M., Lambert, Paul Henri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901381/
https://www.ncbi.nlm.nih.gov/pubmed/33637387
http://dx.doi.org/10.1016/j.vaccine.2021.01.055
Descripción
Sumario:This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission.

Ejemplares similares